



## The Virtual Collaboratory for Integrative Behavioral Health Services Research (VCBH)

*Presents...*

a *Live Webinar* with **Mark McGovern**  
**Friday, March 12, 2010, 2:30pm Eastern**

**“Effectiveness research with co-occurring substance use and psychiatric disorders:  
Considerations in design and measurement”**



**Mark McGovern, PhD**

*Associate Professor of Psychiatry and of Community  
and Family Medicine, Dartmouth Medical School*

**Abstract:** Although research findings are mixed, the preponderance of evidence suggests that integrated treatments for co-occurring disorders are associated with improved outcomes. Policymakers and regulatory authorities are calling for improved services to persons with co-occurring disorders, but increased financial support has not been forthcoming. Researchers and treatment providers are motivated to develop and implement integrated treatments that are readily translated, practical and clearly result in improved outcomes.

This webinar will outline approaches to treatment effectiveness research with co-occurring disorders. The focus will primarily be psychosocial interventions however similar considerations apply to pharmacological studies. Matters to be addressed include: stage of research; identifying the target sample, including inclusion/exclusion criteria; identifying appropriate settings; specification of intervention, including manual development and adherence and competence measure; selecting control or comparison conditions; measurement issues including baseline assessment, outcome and process variables; effect size, power analysis and sample size; and the inevitability of challenges.

The webinar will be designed for interaction and discussion throughout. The goal is to inform and organize discussion about effectiveness research focused on persons with co-occurring substance use and psychiatric disorders.

**If you have any questions about registration or accessing the background readings, please email [info@perpich.com](mailto:info@perpich.com) for more information.**

Funding was made possible by the National Institute on Drug Abuse (1 R13 DA 22908-01, J. Gonzales) with additional support provided by NIMH and NIAAA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Drug Abuse or the National Institutes of Health.